# Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc. is a company headquartered in Devon, PA, United States.

## Company overview

- **Legal name:** Zynerba Pharmaceuticals, Inc.
- **Former names in filing history:** Zynerba Pharmeceuticals, Inc. (2014-10-09 to 2015-06-30)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Devon, PA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001621443

## About

Zynerba Pharmaceuticals, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001621443, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2023-03-28, it reported net income of USD -35,035,806; total assets of USD 55,520,894 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Net income:** -$35.0M (USD -35,035,806)
- **Total assets:** $55.5M (USD 55,520,894)
- **Cash and equivalents:** $50.6M (USD 50,640,993)
- **Operating cash flow:** -$23.0M (USD -23,026,950)

### FY2021 (period ended 2021-12-31)

- **Net income:** -$37.3M (USD -37,309,024)
- **Total assets:** $81.2M (USD 81,171,507)
- **Cash and equivalents:** $67.8M (USD 67,808,000)
- **Operating cash flow:** -$33.5M (USD -33,457,476)

### FY2020 (period ended 2020-12-31)

- **Net income:** -$51.3M (USD -51,336,831)
- **Total assets:** $74.1M (USD 74,056,776)
- **Cash and equivalents:** $59.2M (USD 59,157,187)
- **Operating cash flow:** -$41.3M (USD -41,314,040)

### FY2019 (period ended 2019-12-31)

- **Net income:** -$32.9M (USD -32,943,583)
- **Total assets:** $87.8M (USD 87,764,596)
- **Cash and equivalents:** $70.1M (USD 70,063,242)
- **Operating cash flow:** -$34.8M (USD -34,817,976)

## Recent SEC filings

- Form 8-K — filed 2023-10-11 — period 2023-10-10 — FORM 8-K
- Form SC 13G — filed 2023-09-05
- Form 8-K — filed 2023-08-29 — period 2023-08-25 — FORM 8-K
- Form SC 13D — filed 2023-08-24 — SC 13D
- Form 8-K — filed 2023-08-14 — period 2023-08-14 — FORM 8-K
- Form 10-Q — filed 2023-08-14 — period 2023-06-30 — 10-Q
- Form 8-K — filed 2023-06-14 — period 2023-06-13 — FORM 8-K
- Form 10-Q — filed 2023-05-15 — period 2023-03-31 — 10-Q
- Form 8-K — filed 2023-05-15 — period 2023-05-15 — FORM 8-K
- Form 8-K — filed 2023-05-04 — period 2023-05-02 — FORM 8-K
- Form DEF 14A — filed 2023-04-21 — period 2023-06-13 — DEF 14A
- Form 10-K — filed 2023-03-28 — period 2022-12-31 — 10-K

---

Updated: 2026-10-23T20:09:28Z

Canonical page: https://altss.com/profile/zynerba-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology